Claritev Corp. (CTEV)

NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-15

$22.12-7.29%

Close 2026-10-16 · 1-day change

Claritev Corp. (CTEV) Outlook: What's Priced In | QuarterlyIQ

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Claritev Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Free cash flow turns positive up to $10 million	The company plans positive free cash flow up to $10 million in 2026.	Intact	Free cash flow remains negative for full FY26	Free cash flow: $54.591M FY2026-Q2; GAAP. Published target: >= $0 million and up to $10 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 202654,591,000 USD · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 4
2026-07-25	Unavailable	Unavailable	1 / 4
2026-07-26	Unavailable	Unavailable	1 / 4
2026-07-27	Unavailable	Unavailable	1 / 4
2026-07-28	Unavailable	Unavailable	1 / 4
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Free cash flow turns positive up to $10 millionFree cash flow: $54.591M
Operating income improves to positive territoryOperating income: $23.409M
Quarterly revenue remains near $240 millionRevenue: $257.478M

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-81.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Claritev Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

CTEV represents a turnaround investment with a focus on revenue growth and improving cash flow. The current thesis state is intact, supported by recent strong financial performance despite being loss-making.

What's priced into Claritev Corp.

The market appears to have priced in a low expectations gap, suggesting that CTEV is seen as cheaper compared to its peers. There is a low fragility tier, indicating that current market conditions do not reflect significant risks.

What the fundamentals likely do

Management is on track with priorities to drive revenue growth and improve operating income. However, there is a near-term risk of missing expectations, as the company has had erratic earnings surprises recently.

What Claritev Corp. hinges on

The thesis hinges on management's ability to maintain revenue growth and improve cash flow, as well as external factors like sector performance and economic conditions. Key triggers include guidance updates and sector momentum from bellwether companies.

Bottom line

Over the next 1 to 3 years, CTEV's performance will depend on its execution and external market conditions. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

2026-07-30	Unavailable	Unavailable	2 / 3

2026-07-31	Unavailable	Unavailable	1 / 4

2026-08-01	Unavailable	Unavailable	2 / 3

2026-08-02	Unavailable	Unavailable	1 / 4

2026-08-03	Unavailable	Unavailable	1 / 4

2026-08-04	Unavailable	Unavailable	2 / 3

2026-08-05	Unavailable	Unavailable	1 / 4

2026-08-06	Unavailable	Unavailable	1 / 4

2026-08-07	Unavailable	Unavailable	2 / 3

2026-08-08	Unavailable	Unavailable	1 / 4

2026-08-09	Unavailable	Unavailable	1 / 4

2026-08-10	Unavailable	Unavailable	1 / 4

2026-08-11	Unavailable	Unavailable	1 / 4

2026-08-12	Unavailable	Unavailable	2 / 3

2026-08-13	Unavailable	Unavailable	1 / 4

2026-08-14	Unavailable	Unavailable	2 / 3

2026-08-15	Unavailable	Unavailable	2 / 3

2026-08-16	Unavailable	Unavailable	2 / 3

2026-08-17	Unavailable	Unavailable	2 / 3

2026-08-18	Unavailable	Unavailable	2 / 3

2026-08-19	Unavailable	Unavailable	2 / 3

2026-08-20	Unavailable	Unavailable	2 / 3

2026-08-21	Unavailable	Unavailable	2 / 3

2026-08-22	Unavailable	Unavailable	2 / 3

2026-08-23	Unavailable	Unavailable	2 / 3

2026-08-24	Unavailable	Unavailable	2 / 3

2026-08-25	Unavailable	Unavailable	2 / 3

2026-08-26	Unavailable	Unavailable	2 / 3

2026-08-27	Unavailable	Unavailable	2 / 3

2026-08-28	Unavailable	Unavailable	2 / 3

2026-08-29	Unavailable	Unavailable	2 / 3

2026-08-30	Unavailable	Unavailable	2 / 3

2026-08-31	Unavailable	Unavailable	2 / 3

2026-09-01	Unavailable	Unavailable	2 / 3

2026-09-02	Unavailable	Unavailable	2 / 3

2026-09-03	Unavailable	Unavailable	2 / 3

2026-09-04	Unavailable	Unavailable	2 / 3

2026-09-05	Unavailable	Unavailable	2 / 3

2026-09-06	Unavailable	Unavailable	2 / 3

2026-09-07	Unavailable	Unavailable	2 / 3

2026-09-08	Unavailable	Unavailable	2 / 3

2026-09-09	Unavailable	Unavailable	2 / 3

2026-09-10	Unavailable	Unavailable	2 / 3

2026-09-11	Unavailable	Unavailable	2 / 3

2026-09-12	Unavailable	Unavailable	2 / 3

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	5	1
2026-07-01	5	1
2026-08-01	5	1
2026-09-01	5	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 0 recorded

What could strengthen or challenge Claritev Corp.’s outlook?

Living FV™

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

Claritev Corp. outlook in detail

What kind of bet this is

What's priced into Claritev Corp.

What the fundamentals likely do

What Claritev Corp. hinges on

Bottom line

Analyst view

Price-target changes

Bottom line